We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AgeneBio announced two grant awards to advance their approaches to slowing progression of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD).
MCI due to AD is an intermediate stage between normal cognition and Alzheimer's dementia in which memory and cognitive abilities are markedly worse than expected for a person's age.